CD44 and breast carcinoma: We have recently shown in our laboratory, in a cohort of 78 patients with breast cancer, that those classified as Luminal B and TN who received neoadjuvant therapy before surgery, present an increase in the frequency of BCSC with a CD44+/CD24−/EPCAM+/CD49f+ phenotype together with the expression of ALDH compared to healthy donor tissue.